60 DEGREES PHARMA INC (SXTP) Stock Price, Forecast & Analysis
NASDAQ:SXTP • US83006G5009
SXTP Key Statistics, Chart & Performance
The current stock price of SXTP is 2.96 USD. In the past month the price decreased by -43.08%. In the past year, price decreased by -59.12%.
SXTP Technical Analysis
SXTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. Both the profitability and financial health of SXTP have multiple concerns.
SXTP Financial Highlights
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -23.4. The EPS increased by 48.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -126.7% | ||
| ROE | -191.31% | ||
| Debt/Equity | 0.03 |
SXTP Forecast & Estimates
8 analysts have analysed SXTP and the average price target is 17.95 USD. This implies a price increase of 506.49% is expected in the next year compared to the current price of 2.96.
For the next year, analysts expect an EPS growth of 65.93% and a revenue growth 164.27% for SXTP
SXTP Ownership
SXTP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.45 | 972.635B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 590.688B | ||
| MRK | MERCK & CO. INC. | 22.05 | 303.948B | ||
| PFE | PFIZER INC | 9.02 | 154.026B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.04 | 124.791B | ||
| ZTS | ZOETIS INC | 18.89 | 56.827B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.062B | ||
| VTRS | VIATRIS INC | 6.03 | 18.521B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.05 | 13.336B | ||
| AXSM | AXSOME THERAPEUTICS INC | 199.27 | 8.278B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SXTP
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Company Info
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Phone: 12023275422
60 DEGREES PHARMA INC / SXTP FAQ
What does SXTP do?
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
What is the stock price of 60 DEGREES PHARMA INC today?
The current stock price of SXTP is 2.96 USD. The price decreased by -3.58% in the last trading session.
Does SXTP stock pay dividends?
SXTP does not pay a dividend.
What is the ChartMill technical and fundamental rating of SXTP stock?
SXTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for SXTP stock?
The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 164.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of 60 DEGREES PHARMA INC (SXTP)?
You can find the ownership structure of 60 DEGREES PHARMA INC (SXTP) on the Ownership tab.